SillaJen Biotherapeutics, 450 Sansome Street, Suite 650, San Francisco, CA 94111, United States.
University of Southern California, Norris Comprehensive Cancer Center, 1441 Eastlake Avenue #3440, Los Angeles, CA 90033, United States.
Curr Opin Virol. 2015 Aug;13:55-60. doi: 10.1016/j.coviro.2015.03.020. Epub 2015 May 16.
Developing a live anti-cancer agent derived in most cases from human pathogens presents a unique set of challenges to clinical development versus those anticipated with standard chemotherapeutics and small molecules. The selection of therapeutic targets for oncolytic virus (OV) clinical development, as is true with the development of any agent for cancer therapy, requires careful consideration beyond preclinical and early clinical data, especially when multiple indications may initially appear equally promising. Further, the added complexity of the potential for infectious complications following OV therapy must be anticipated in order to efficiently and safely conduct clinical studies. As more OV enter the clinic, these issues will become increasingly important to successful OV drug development.
与标准化疗药物和小分子药物相比，开发大多数源自人类病原体的抗癌活性药物，在临床开发方面带来了独特的挑战。与癌症治疗的任何药物的开发一样，溶瘤病毒（OV）临床开发的治疗靶点选择需要仔细考虑临床前和早期临床数据以外的因素，特别是当多个适应症最初看起来同样有希望时。此外，必须预料到 OV 治疗后发生感染并发症的潜在复杂性，以便有效地和安全地进行临床研究。随着越来越多的 OV 进入临床，这些问题对于成功开发 OV 药物将变得越来越重要。
